98%
921
2 minutes
20
The objective of this study was to identify novel autoantibodies specific for open-angle glaucoma (OAG), including normal-tension glaucoma (NTG) and primary open-angle glaucoma (POAG), using proteome-wide autoantibody screening and to determine their utility for diagnosis. We conducted proteome-wide autoantibody screening by wet protein arrays. Autoantibody reactivity in the plasma of OAG patients (50 NTG and 69 POAG patients) was quantitatively analyzed and compared to that of controls (35 cataract patients). The area under the curve (AUC) of the receiver operating characteristic (ROC) and multivariate analyses were used to determine diagnostic potential in patients with OAG. Based on differences in autoantibody titers and positivity rates, four autoantibodies against ETNK1, VMAC, NEXN, and SUN1 were selected as potential biomarkers to discriminate OAG and cataract. In discrimination between POAG and cataract, the AUCs of ETNK1 and VMAC were calculated to be 0.820 (95%CI: 0.733-0.907) and 0.889 (95%CI: 0.818-0.959), respectively. Furthermore, the combination of these four antibodies demonstrated diagnostic potential for OAG with an AUC of 0.828 (95%CI: 0.757-0.898) by multivariate analysis. Four new glaucoma-associated autoantibodies were identified in this study. The differences in autoantibody patterns in the plasma between glaucoma and cataract patients support their potential utility as biomarkers for glaucoma screening.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940370 | PMC |
http://dx.doi.org/10.3390/biomedicines13030718 | DOI Listing |
J Glaucoma
September 2025
Department of Ophthalmology, University of Campinas, Campinas, São Paulo, Brazil.
Prcis: Gonioscopy-Assisted Transluminal Trabeculotomy achieved a higher success rate than Bent Ab interno Needle Goniotomy in pseudophakic primary open angle glaucoma eyes at 12-months.
Purpose: To evaluate and compare efficacy and safety of standalone Bent Ab interno Needle Goniotomy (BANG) and Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) in pseudophakic primary open angle glaucoma (POAG) eyes.
Methods: Parallel, double-arm, 1:1 ratio, single masked, single surgeon, randomized clinical trial.
Retina
June 2025
Ophthalmology Department 5, National Hospital 15-20, Paris, France.
Zhonghua Yan Ke Za Zhi
September 2025
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.
The rise of minimally invasive glaucoma surgery (MIGS) has brought new options to glaucoma treatment. However, there are significant differences between MIGS and traditional trabeculectomy in terms of surgical philosophy, applicable populations, and long-term efficacy. As a classic procedure, trabeculectomy achieves a well-documented intraocular pressure (IOP)-lowering effect but is associated with a higher risk of complications.
View Article and Find Full Text PDFVestn Oftalmol
September 2025
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Primary open-angle glaucoma (POAG) is characterized by chronic progressive damage to the retinal ganglion cell layer (GCL) and their axons, leading to gradual visual function loss. Currently, the gold standards for structural and functional assessment of the retina in glaucoma are static automated perimetry (SAP) and optical coherence tomography (OCT). However, in clinical practice, data from SAP and OCT may be insufficient to reliably determine the stage of glaucomatous optic neuropathy, monitor its progression, or differentiate it from other causes of visual dysfunction.
View Article and Find Full Text PDFVestn Oftalmol
September 2025
OOO Diagnosticheskij tsentr Zreniye, Saint Petersburg, Russia.
Objective: This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG).
Material And Methods: The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally).